Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Pain Management

PUBLISHER: Grand View Research | PRODUCT CODE: 1493216

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1493216

Cannabis Pharmaceuticals Market Size, Share & Trends Analysis Report By Brand Type (Sativex, Epidiolex, Other Brands), By Region (North America, Middle East And Africa, Asia Pacific, Europe), And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Cannabis Pharmaceuticals Market Growth & Trends:

The global cannabis pharmaceuticals market size is expected to reach USD 102.4 billion by 2030, expanding at a CAGR of 53.3% from 2024 to 2030, according to a new study by Grand View Research, Inc. Growing use of cannabis in various medical applications is driving the global pharmaceutical cannabis market growth. For instance, cannabis is widely used for treating patients suffering from chronic conditions, such as Parkinson's disease, cancer, arthritis, and Alzheimer's disease, as well as neurologic problems, such as depression, anxiety, & epilepsy. Moreover, there is a growing disease burden of chronic pain and pain management therapies. This, in turn, is increasing cannabis product consumption as it is effective in pain management.

The market has undergone substantial changes in recent years, driven by increased global acceptance and legalization for medical use. This development has led to a notable rise in patent applications for cannabis-based pharmaceuticals. For instance, in October 2023, SciSparc Ltd., a specialized clinical-stage pharmaceutical company focusing on creating treatments for central nervous system disorders and rare diseases, announced that its patent application for the Combinations of Cannabinoids and N-Acylethanolamines (the "Patent") had been officially accepted. The patent was awarded by IP Australia, the Australian government agency responsible for managing intellectual property rights and patent legislation. Accepting such patents is vital for promoting innovation, allowing companies to safeguard their inventions and stimulate further research and development. This trend is expected to persist as the medicinal benefits of cannabinoids gain wider acknowledgment, potentially offering new treatment options for patients worldwide.

Furthermore, various companies and research institutes in the cannabis industry are conducting research studies to validate claims associated with CBD products, which is fueling market growth. This trend is further supported by the introduction of innovative products to meet the increasing consumer demand. According to the U.S. Food and Drug Administration (FDA) study published in February 2023, the FDA has given its approval to Epidiolex, a medication that contains a refined version of cannabidiol (CBD), for the treatment of seizures linked to Lennox-Gastaut syndrome or Dravet syndrome in patients aged 2 years and above. The FDA has also authorized the use of Marinol and Syndros for medical purposes in the U.S. These medications are approved for improving nausea caused by cancer chemotherapy and for managing anorexia leading to weight loss in patients with AIDS. In November 2021, Colorado State University inaugurated a new research center dedicated to CBD. Similarly, in the same month, AMP Alternative Medical Products GmbH, a subsidiary of Greenrise Global Brands, Inc., launched a Dronabinol product in the German market.

Moreover, companies are implementing diverse strategies to enhance their market presence. For instance, in March 2024, Brains Bioceutical Corp, also known as Brains Bio, a company in the pharmaceutical industry's cannabinoid sector, revealed its achievement in developing the world's first solid form of Tetrahydrocannabinol (THC) for use as an Active Pharmaceutical Ingredient (API). In November 2021, Avicanna, a biopharmaceutical firm, finalized an intellectual property (IP) and distribution agreement with a well-established pharmaceutical company in Argentina. As part of this agreement, Avicanna is expected to grant a nonexclusive license for its proprietary 10% CBD pharmaceutical drug preparation.

Cannabis Pharmaceuticals Market Report Highlights:

  • Based on brand type, Epidiolex segment accounted for the revenue share in 2023 owing to the high demand among healthcare practitioners and patients for medicinal cannabis
  • In 2023, Europe dominated the overall market with a revenue share of 41.9% owing to increasing cannabis consumption, as well as rising awareness and positive attitude towards cannabis and its products. North America was among the first regions to legalize the use of medical and recreational cannabis.
  • Some of the major players operating in this space are Jazz Pharmaceuticals, Inc., AbbVie, Inc., Insys Therapeutics, Inc., Bausch Health Companies, Inc.
Show more
Product Code: GVR-4-68038-473-4

Table of Contents

Chapter 1. Cannabis Pharmaceuticals Market: Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Brand Type
    • 1.2.2. Regional scope
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Cannabis Pharmaceuticals Market: Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Brand type outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Cannabis Pharmaceuticals Market: Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Cannabis Pharmaceuticals Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Cannabis Pharmaceuticals Market: Brand Type Estimates & Trend Analysis

  • 4.1. Brand Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Cannabis Pharmaceuticals Market by Brand Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Sativex
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Epidiolex
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Other Brands
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Cannabis Pharmaceuticals Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Share Analysis, 2023 & 2030
  • 5.2. Regional Market Dashboard
  • 5.3. Global Regional Market Snapshot
  • 5.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 5.5. North America
    • 5.5.1. U.S.
      • 5.5.1.1. Key country dynamics
      • 5.5.1.2. Regulatory framework/ reimbursement structure
      • 5.5.1.3. Competitive scenario
      • 5.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. Canada
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Regulatory framework/ reimbursement structure
      • 5.5.2.3. Competitive scenario
      • 5.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Europe
    • 5.6.1. UK
      • 5.6.1.1. Key country dynamics
      • 5.6.1.2. Regulatory framework/ reimbursement structure
      • 5.6.1.3. Competitive scenario
      • 5.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.2. Germany
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Regulatory framework/ reimbursement structure
      • 5.6.2.3. Competitive scenario
      • 5.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.3. France
      • 5.6.3.1. Key country dynamics
      • 5.6.3.2. Regulatory framework/ reimbursement structure
      • 5.6.3.3. Competitive scenario
      • 5.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.4. Netherlands
      • 5.6.4.1. Key country dynamics
      • 5.6.4.2. Regulatory framework/ reimbursement structure
      • 5.6.4.3. Competitive scenario
      • 5.6.4.4. Netherlands market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.5. Italy
      • 5.6.5.1. Key country dynamics
      • 5.6.5.2. Regulatory framework/ reimbursement structure
      • 5.6.5.3. Competitive scenario
      • 5.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.6. Spain
      • 5.6.6.1. Key country dynamics
      • 5.6.6.2. Regulatory framework/ reimbursement structure
      • 5.6.6.3. Competitive scenario
      • 5.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.7. Croatia
      • 5.6.7.1. Key country dynamics
      • 5.6.7.2. Regulatory framework/ reimbursement structure
      • 5.6.7.3. Competitive scenario
      • 5.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.8. Poland
      • 5.6.8.1. Key country dynamics
      • 5.6.8.2. Regulatory framework/ reimbursement structure
      • 5.6.8.3. Competitive scenario
      • 5.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.9. Czech Republic
      • 5.6.9.1. Key country dynamics
      • 5.6.9.2. Regulatory framework/ reimbursement structure
      • 5.6.9.3. Competitive scenario
      • 5.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.10. Switzerland
      • 5.6.10.1. Key country dynamics
      • 5.6.10.2. Regulatory framework/ reimbursement structure
      • 5.6.10.3. Competitive scenario
      • 5.6.10.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Asia Pacific
    • 5.7.1. Japan
      • 5.7.1.1. Key country dynamics
      • 5.7.1.2. Regulatory framework/ reimbursement structure
      • 5.7.1.3. Competitive scenario
      • 5.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.2. Australia
      • 5.7.2.1. Key country dynamics
      • 5.7.2.2. Regulatory framework/ reimbursement structure
      • 5.7.2.3. Competitive scenario
      • 5.7.2.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.3. New Zealand
      • 5.7.3.1. Key country dynamics
      • 5.7.3.2. Regulatory framework/ reimbursement structure
      • 5.7.3.3. Competitive scenario
      • 5.7.3.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Latin America
    • 5.8.1. Brazil
      • 5.8.1.1. Key country dynamics
      • 5.8.1.2. Regulatory framework/ reimbursement structure
      • 5.8.1.3. Competitive scenario
      • 5.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.2. Mexico
      • 5.8.2.1. Key country dynamics
      • 5.8.2.2. Regulatory framework/ reimbursement structure
      • 5.8.2.3. Competitive scenario
      • 5.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.3. Argentina
      • 5.8.3.1. Key country dynamics
      • 5.8.3.2. Regulatory framework/ reimbursement structure
      • 5.8.3.3. Competitive scenario
      • 5.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.4. Colombia
      • 5.8.4.1. Key country dynamics
      • 5.8.4.2. Regulatory framework/ reimbursement structure
      • 5.8.4.3. Competitive scenario
      • 5.8.4.4. Colombia market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.5. Uruguay
      • 5.8.5.1. Key country dynamics
      • 5.8.5.2. Regulatory framework/ reimbursement structure
      • 5.8.5.3. Competitive scenario
      • 5.8.5.4. Uruguay market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.6. Chile
      • 5.8.6.1. Key country dynamics
      • 5.8.6.2. Regulatory framework/ reimbursement structure
      • 5.8.6.3. Competitive scenario
      • 5.8.6.4. Chile market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.7. Peru
      • 5.8.7.1. Key country dynamics
      • 5.8.7.2. Regulatory framework/ reimbursement structure
      • 5.8.7.3. Competitive scenario
      • 5.8.7.4. Peru market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. MEA
    • 5.9.1. South Africa
      • 5.9.1.1. Key country dynamics
      • 5.9.1.2. Regulatory framework/ reimbursement structure
      • 5.9.1.3. Competitive scenario
      • 5.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.9.2. Isarel
      • 5.9.2.1. Key country dynamics
      • 5.9.2.2. Regulatory framework/ reimbursement structure
      • 5.9.2.3. Competitive scenario
      • 5.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
  • 6.3. Vendor Landscape
    • 6.3.1. List of key distributors and channel partners
    • 6.3.2. Key customers
    • 6.3.3. Key company market share analysis, 2023
    • 6.3.4. Canopy Growth Corporation
      • 6.3.4.1. Company overview
      • 6.3.4.2. Financial performance
      • 6.3.4.3. Product benchmarking
      • 6.3.4.4. Strategic initiatives
    • 6.3.5. Jazz Pharmaceuticals, Inc.
      • 6.3.5.1. Company overview
      • 6.3.5.2. Financial performance
      • 6.3.5.3. Product benchmarking
      • 6.3.5.4. Strategic initiatives
    • 6.3.6. AbbVie, Inc.
      • 6.3.6.1. Company overview
      • 6.3.6.2. Financial performance
      • 6.3.6.3. Product benchmarking
      • 6.3.6.4. Strategic initiatives
    • 6.3.7. Insys Therapeutics, Inc.
      • 6.3.7.1. Company overview
      • 6.3.7.2. Financial performance
      • 6.3.7.3. Product benchmarking
      • 6.3.7.4. Strategic initiatives
    • 6.3.8. Bausch Health Companies, Inc.
      • 6.3.8.1. Company overview
      • 6.3.8.2. Financial performance
      • 6.3.8.3. Product benchmarking
      • 6.3.8.4. Strategic initiatives
Show more
Product Code: GVR-4-68038-473-4

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America cannabis pharmaceuticals market, 2018 - 2030 (USD Million)
  • Table 3 North America cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 4 U.S. cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 5 Canada cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 6 Europe cannabis pharmaceuticals market, by country, 2018 - 2030 (USD Million)
  • Table 7 Europe cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 8 Germany cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 9 UK cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 10 Netherlands cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 11 France cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 12 Italy cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 13 Spain cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 14 Croatia cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 15 Poland cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 16 Czech Republic cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 17 Switzerland cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 18 Asia Pacific cannabis pharmaceuticals market, by country, 2018 - 2030 (USD Million)
  • Table 19 Asia Pacific cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 20 Japan cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 21 New Zealand cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 22 Australia cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 23 South Korea cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 24 Latin America cannabis pharmaceuticals market, by country, 2018 - 2030 (USD Million)
  • Table 25 Latin America cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 26 Brazil cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 27 Argentina cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 28 Mexico cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 29 Uruguay cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 30 Colombia cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 31 Chile cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 32 Peru cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 33 MEA cannabis pharmaceuticals market, by country, 2018 - 2030 (USD Million)
  • Table 34 MEA cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 35 South Africa cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)
  • Table 36 Israel cannabis pharmaceuticals market, by brand type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Cannabis pharmaceuticals market: market outlook
  • Fig. 9 Cannabis pharmaceuticals competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Cannabis pharmaceuticals market driver impact
  • Fig. 15 Cannabis pharmaceuticals market restraint impact
  • Fig. 16 Cannabis pharmaceuticals market strategic initiatives analysis
  • Fig. 17 Cannabis pharmaceuticals market: Brand type movement analysis
  • Fig. 18 Cannabis pharmaceuticals market: Brand type outlook and key takeaways
  • Fig. 19 Sativex market estimates and forecast, 2018 - 2030
  • Fig. 20 Epidiolex market estimates and forecast, 2018 - 2030
  • Fig. 21 Other brands market estimates and forecast, 2018 - 2030
  • Fig. 22 Global Cannabis pharmaceuticals market: Regional movement analysis
  • Fig. 23 Global Cannabis pharmaceuticals market: Regional outlook and key takeaways
  • Fig. 24 Global Cannabis pharmaceuticals market share and leading players
  • Fig. 25 North America market share and leading players
  • Fig. 26 Europe market share and leading players
  • Fig. 27 Asia Pacific market share and leading players
  • Fig. 28 Latin America market share and leading players
  • Fig. 29 Middle East & Africa market share and leading players
  • Fig. 30 North America, by country
  • Fig. 31 North America
  • Fig. 32 North America market estimates and forecasts, 2018 - 2030
  • Fig. 33 U.S.
  • Fig. 34 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 35 Canada
  • Fig. 36 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 37 Europe
  • Fig. 38 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 39 UK
  • Fig. 40 UK market estimates and forecasts, 2018 - 2030
  • Fig. 41 Germany
  • Fig. 42 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 43 Netherlands
  • Fig. 44 Netherlands market estimates and forecasts, 2018 - 2030
  • Fig. 45 France
  • Fig. 46 France market estimates and forecasts, 2018 - 2030
  • Fig. 47 Italy
  • Fig. 48 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 49 Spain
  • Fig. 50 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 51 Croatia
  • Fig. 52 Croatia market estimates and forecasts, 2018 - 2030
  • Fig. 53 Poland
  • Fig. 54 Poland market estimates and forecasts, 2018 - 2030
  • Fig. 55 Czech Republic
  • Fig. 56 Czech Republic market estimates and forecasts, 2018 - 2030
  • Fig. 57 Switzerland
  • Fig. 58 Switzerland market estimates and forecasts, 2018 - 2030
  • Fig. 59 Asia Pacific
  • Fig. 60 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 61 Japan
  • Fig. 62 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 63 South Korea
  • Fig. 64 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 65 New Zealand
  • Fig. 66 New Zealand market estimates and forecasts, 2018 - 2030
  • Fig. 67 Australia
  • Fig. 68 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 69 Latin America
  • Fig. 70 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 71 Brazil
  • Fig. 72 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 73 Mexico
  • Fig. 74 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 75 Argentina
  • Fig. 76 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 77 Colombia
  • Fig. 78 Colombia market estimates and forecasts, 2018 - 2030
  • Fig. 79 Uruguay
  • Fig. 80 Uruguay market estimates and forecasts, 2018 - 2030
  • Fig. 81 Chile
  • Fig. 82 Chile market estimates and forecasts, 2018 - 2030
  • Fig. 83 Peru
  • Fig. 84 Peru market estimates and forecasts, 2018 - 2030
  • Fig. 85 Middle East and Africa
  • Fig. 86 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 87 South Africa
  • Fig. 88 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 89 Israel
  • Fig. 90 Israel Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 91 Market position analysis of key market players - Cannabis pharmaceuticals market
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!